Lixte Biotechnology Holdings, Inc.(LIXT)Earnings, Financials & Key RatiosLixte Biotechnology Holdings, Inc. (LIXT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's rapid depletion of cash reserves from $5.1 million in 2025Q4 to $3.3 million in 2026Q1, combined with a lack of revenue, presents an unsustainable risk profile for long-term investors.
Lixte Biotechnology Holdings, Inc. (LIXT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Recent stock market news and headlines for Lixte Biotechnology Holdings, Inc. (LIXT)
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions BOCA RATON, Fla. /WATERBURY, Vt. , July 02, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) ("LIXTE" or the "Company") today announced it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc.
BOCA RATON, Fla. , June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap Index, effective after the close of the U. S. equity markets on June 26, 2026, as part of the annual Russell U.
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap® Index, effective after the close of the U.S. equity markets on June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution. The reconstituted indexes will take effect at the opening of trading on Monday, June 29, 2026.
Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA RATON, Fla. & WATERBURY, Vt.
Key metrics vs top competitors for Lixte Biotechnology Holdings, Inc. (LIXT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.21 | $78.51M | -5.72 | — | — | -101.95% | — | |
| $0.86 | $96.1M | -2.97 | — | — | — | — | |
| $0.15 | $2.33M | -0.06 | -15.77% | -183.93% | — | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — |
Lixte Biotechnology Holdings, Inc. (LIXT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Lixte Biotechnology Holdings, Inc. (LIXT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 17, 2026·SEC
Mar 20, 2026·SEC
Mar 10, 2026·SEC
Get notified when LIXT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lixte Biotechnology Holdings, Inc. (LIXT) stock FAQ — growth, dividends, profitability & financials explained
Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $7.3M for fiscal year 2025.
Lixte Biotechnology Holdings, Inc. (LIXT) has a return on equity (ROE) of -102.0%. Negative ROE indicates the company is unprofitable.
Lixte Biotechnology Holdings, Inc. (LIXT) had negative free cash flow of $4.4M in fiscal year 2025, likely due to heavy capital investments.
